Roche's non-small cell lung cancer treatment Gavreto (Pralsetinib)"has obtained an item license in Korea.

The MFDS approved Gavreto 100mg on the 29th. The drug was recognized for its effectiveness in the treatment of ▲RET (RET) fusion-positive local progression or metastatic non-small cell lung cancer adult patients and ▲ systemic therapy required RET mutation local progression or metastatic thyroid medullary cancer for adult patients. The effectiveness is based on the reaction rate and reaction period, and there is no data proving the improvement of the survival period.

According to 136 patients who have been administered platinum-based chemotherapy drugs and have been administered Gav